BETA vs RUBICON: Stock Comparison
RUBICON RESEARCH is the larger company by market capitalisation. BETA DRUGS shows a lower P/E, while RUBICON RESEARCH shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BETA leads 3; RUBICON leads 10 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BETA | RUBICON |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | BETA | RUBICON |
|---|---|---|
| Live Price | ₹2,079 | ₹1,791.8 |
| Day Change | 0.68% | 1.42% |
| Volume | 4,664 | 1.17 L |
| 52-Week High | ₹2,807.9 | ₹1,899 |
| 52-Week Low | ₹990.1 | ₹570.75 |
| Distance from 52W High | -25.96% | -5.65% |
Valuation
| Metric | BETA | RUBICON |
|---|---|---|
| Market Cap | ₹2,303 Cr | ₹29,632 Cr |
| P/E Ratio | 50.32x | 102.12x |
| P/B Ratio | 8.53x | 22.84x |
| EPS | ₹5.35 | ₹4.99 |
| Book Value | ₹220.79 | ₹77.93 |
| Dividend Yield | 0% | 0.08% |
Growth
| Metric | BETA | RUBICON |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 43.5% |
| EPS Growth (TTM YoY) | 0% | 96.6% |
| Qtr Sales Growth | -55.53% | -19.95% |
| Qtr Profit Growth | -64.01% | -2.75% |
Profitability & Leverage
| Metric | BETA | RUBICON |
|---|---|---|
| ROE | 9.58% | 19.14% |
| ROCE | 14.63% | 20.49% |
| Net Margin | 10.78% | 13.48% |
| Operating Margin | 13.32% | 20.68% |
| Debt to Equity | 0.87x | 0.2x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BETA | RUBICON |
|---|---|---|
| Promoter Holding | 59.1%▼ 5.53 pp | 23.93%▼ 0.04 pp |
| FII Holding | 1.02%▼ 0.14 pp | 7.52%▼ 0.02 pp |
| DII Holding | 6.23%▲ 4.08 pp | 9.43%▼ 0.59 pp |
| Public Holding | 33.65%▲ 1.59 pp | 23.3%▲ 0.72 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BETA DRUGS and RUBICON RESEARCH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.